Comparative Pharmacology
Head-to-head clinical analysis: TEPMETKO versus XALKORI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEPMETKO versus XALKORI.
TEPMETKO vs XALKORI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
Selective tyrosine kinase inhibitor targeting ALK, ROS1, and MET, inhibiting downstream signaling pathways (PI3K/AKT, MAPK/ERK) leading to reduced tumor cell proliferation and survival.
450 mg orally once daily with food.
250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Terminal elimination half-life is approximately 72 hours (range 47-108 hours) in patients, supporting once-daily dosing.
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Primarily hepatic metabolism, with 53% of the dose recovered in feces (mostly as metabolites) and 22% in urine (1.1% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor